AMA CPT® Assistant - 2020 Issue 10 (October)
New Molecular Testing Code for Prostate Cancer (October 2020)
October 2020 page 8 New Molecular Testing Code for Prostate Cancer In the Current Procedural Terminology (CPT®) 2020 code set, a new Category I code (81542) was established in the Multianalyte Assays with Algorithmic Analyses (MAAA) subsection to report mRNA analysis of 22 content genes, including profiling and creation of a calculated risk score for prostate cancer metastasis (Decipher® Prostate test). Previously, this test was reported with code 81479, Unlisted molecular pathology procedure. This article provides a brief overview of this new code. Multianalyte Assays with Algorithmic Analyses 81542Oncology (prostate), mRNA, microarray gene expression profiling of 22 content...
Subscribe or sign in to view the full article.
Article Overview
This article explains a new CPT 2020 molecular testing code related to prostate cancer and summarizes the testing context, where it fits in the CPT structure, and the type of clinical scenario associated with it. It is intended for coders, billing staff, and clinical documentation teams who need to understand the scope of the update and how the code is presented in the CPT assistant discussion.
Why This Topic Matters
It helps readers recognize that a prostate cancer gene-expression assay was added to CPT 2020 and see how the article frames the test, its setting, and the surrounding reporting guidance.
Article Sections
-
October 2020 page 8
Publication placement information for the article.
-
Multianalyte Assays with Algorithmic Analyses
An overview of the CPT subsection in which the new molecular testing code appears and the general context for MAAA reporting.
-
Clinical Example and Description of Procedure
A representative clinical scenario and a procedural overview illustrating the type of testing addressed by the article.
What You Will Learn
- Where the new prostate cancer molecular testing code is located within CPT.
- What general testing context the article associates with the code.
- How the article frames the clinical scenario and procedure overview surrounding the code.
- What prior reporting approach the article notes in relation to the new code.
Who Should Read This
- Medical coders
- Billing specialists
- Compliance staff
- Clinical documentation teams
- Pathology and molecular diagnostics professionals
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com